Abstracts tagged "Scleroderma"

Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 2471 • ACR Convergence 2025
Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
Borja del Carmelo Gracia Tello¹, Gema María Lledó Ibáñez², Luis Sáez Comet³ and Eduardo Ramos ibáñez⁴, ¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold capillaroscopy is a key tool in the early diagnosis of systemic sclerosis and related disorders. However, incorrect image acquisition can lead to misclassification…
Abstract Number: 1589 • ACR Convergence 2025
Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
Punchalee Kaenmuang¹, Nina Goldman², Arthihai Srirangan¹, Fiammetta Danzo¹, Wing-Ho Yip¹, Ali Taki³, Shereen Boreland¹, Benedetta Vitri¹, Carmel JW. Stock¹, Christopher Denton⁴, Athol U. Wells¹, Voon H. Ong⁵, Piersante Sestini⁶ and Elisabetta A. Renzoni¹, ¹Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy’s and St Thomas’ National Health Service Foundation Trust, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Royal Free Hospital, London, England, United Kingdom, ⁴University College London, UK, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁶Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Toscana, Italy
Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…
Abstract Number: 0971 • ACR Convergence 2025
Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
Neha Khanna¹, Alyssa Rosek¹, Alexander Cai¹, Olesya Plazyo², Johann Gudjonsson², Dinesh Khanna² and Pei-Suen Tsou², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by excessive collagen production, leading to the thickening and hardening of skin and internal organs.…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Rachel Guess¹, Megan Curran², Lisa Zickuhr³ and Rachel Moquin¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Colorado | Children's Hospital Colorado, Aurora, CO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…
Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Marissa Savoie¹, Monica Harding², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon¹, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin¹, Dorota Lebiedz-Odrobina², Yiming Luo⁴, Ashima Makol¹¹, Maureen Mayes¹², Zsuzsanna McMahan¹³, Jerry Molitor¹⁴, Duncan Moore¹⁵, Carrie Richardson¹⁶, Nora Sandorfi¹⁷, Ami Shah⁹, Ankoor Shah¹⁸, Brian Skaug¹⁹, Virginia Steen²⁰, Elizabeth Volkmann²¹, Carleigh Zahn¹⁰ and Flavia Castelino²², ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University, Stanford, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Mayo Clinic, Rochester, MN, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³UT Health Houston, Houston, TX, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Northwestern Memorial Hospital, Chicago, IL, ¹⁶Northwestern University, Chicago, IL, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Duke University, Durham, NC, ¹⁹UTHealth Houston Division of Rheumatology, Houston, TX, ²⁰Georgetown University School of Medicine, Washington, DC, ²¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²²Massachusetts General Hospital, Boston, MA
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
Abstract Number: 0965 • ACR Convergence 2025
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
Kamal Saba¹, Rong Huang², Priyanka Verma¹, M Asif Amin¹ and John Varga¹, ¹University of Michigan, Ann Arbor, MI, ²Purdue University, West Lafayette, IN
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…
Abstract Number: 0681 • ACR Convergence 2025
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
Aïcha Kante¹, Sandra Mghaieth², bertrand Dunogue³, Alice berezne³, Cloé Comarmond¹, Marie-Pierre Revel², Guillaume Chassagnon², Luc Mouthon³ and Benjamin Chaigne³, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Radiology Department, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…
Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Patompong Ungprasert¹ and Paul Kroner², ¹Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, ²Riverside Health System, Newport News, VA
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
Abstract Number: 0966 • ACR Convergence 2025
Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
kristina clark¹, Xu Shiwen², Xue Li², Voon H. Ong³ and Christopher Denton⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, ²University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 1969 • ACR Convergence 2025
Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Genessis Maldonado¹, Sowmika Rao¹ and Tracy Frech², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Raynaud’s phenomenon (RP) is a painful and disabling feature of systemic sclerosis (SSc) that significantly impairs quality of life. Tools that integrate subjective symptom…
Abstract Number: 1574 • ACR Convergence 2025
A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease
Keina Yomono¹, Suiyuan Huang², Dinesh Khanna² and Masataka Kuwana³, ¹Nippon Medical School, Bunkyo-ku, Tokyo, Japan, ²University of Michigan, Ann Arbor, MI, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Given the high variable clinical course of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].